Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
| 17.59 | |
| 17.61 | |
| - | |
| 17.86 | |
| 17.38 | |
| 11.55-17.99 | |
| 2 052 M | |
| 31.0179 | |
| 118 M | |
| 411 M | |
| 0.19 | |
| 0.703 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical com...
A month has gone by since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 0.7% in that time frame, underperforming the S&P 500. Will the recent positive trend con...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
